Interest-bearing debt
Pass0.0%of market cap
0%limit 30%
UK annual report (ESEF), FY ending 2024-12-31: no borrowings; every liability line is accounted for in the filed totals
HEMO.L
London prices aren’t shown yet.
Verdict
The business and both balance-sheet tests pass, but Hemogenyx Pharmaceuticals plc doesn't report a current twelve-month interest-income figure, so the 5% income test can't be applied. We don't estimate it.
AAOIFI Shari'ah Standard No. 21 · not certified · screened 15 Oct 2026
Each bar shows the figure against its limit; the line marks the limit.
0.0%of market cap
UK annual report (ESEF), FY ending 2024-12-31: no borrowings; every liability line is accounted for in the filed totals
0.4%of market cap
UK annual report (ESEF), FY ending 2024-12-31, converted from GBP at the ECB rate of 2026-10-15
—of revenue
No prohibited activity (alcohol, gambling, tobacco, conventional finance, pork, adult content) found in the sector, SEC industry or company name.
See the business + financial screening, dividend purification ratio, and category-by-category compliance status.
Upgrade to ProNo current twelve-month interest-income figure in the company's filings.